Munich AVONTEC GmbH, a biotechnology company specialized in the research and development of new anti-inflammatory drugs, has raised Euro 14.5 million in its second round of financing. AVONTEC will use the funding primarily to conduct further clinical trials in the area of inflammatory diseases, such as asthma and psoriasis. The financing round was led by AnGes MG, Japan, which made the investment through its Bio-sight Innovation investment vehicle. The round was co-led by DVC Deutsche Venture Capital. BioMedinvest from Switzerland also participated in this financing round as well as all existing investors.